NCT07709312Not yet recruitingPhase 2/3
the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patients
The Effect of Gingko Biloba on the Clinical Outcome of Rheumatoid Arthritis Patients
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
this study aims to measure The Effect of Gingko Biloba on the Clinical Outcome of Rheumatoid Arthritis Patients ,the outcomes are hsCRp,calprotectin,DAS-28,HAQ-DI
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 12 Jul 2026
- Start date
- 15 Oct 2026
- Primary completion date
- 15 Jan 2027
- Lead sponsor
- Ain Shams University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07709312
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 50
- From 15 Oct 2026 to the primary completion date, 15 Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Adult patients (older than 18 years) -
- With moderate to high disease activity defined as DAS-28 score ≥ 3.2
- Patients receiving stable regimen of one or more csDMARDs for the past 6 months Exclusion criteria
- Patients with known hypersensitivity to Ginkgo biloba
- Patients receiving Ginkgo biloba for any other indications
- Patients on biologic DMARDs
- Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \< 30 ml/min),
- Patients with any of the following comorbidities: congestive heart failure, history of myocardial infarction, severe anemia, active infections, other inflammatory diseases, and malignancies.
- Patients with other autoimmune diseases
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.